CTLA4 and non-small cell lung carcinoma: In a recent clinical trial, Formenti and colleagues tested two palliative radiation schemes (3 × 9Gy versus 5 × 6Gy) in combination with anti-CTLA-4 in 39 chemorefractory NSCLC patients.